503 related articles for article (PubMed ID: 28467795)
1. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
4. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
5. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
8. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Shields LB; Kadner R; Vitaz TW; Spalding AC
Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
[TBL] [Abstract][Full Text] [Related]
9. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
11. Time trends in glioblastoma multiforme survival: the role of temozolomide.
Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
[TBL] [Abstract][Full Text] [Related]
12. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
14. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Rønning PA; Helseth E; Meling TR; Johannesen TB
Neuro Oncol; 2012 Sep; 14(9):1178-84. PubMed ID: 22869622
[TBL] [Abstract][Full Text] [Related]
15. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
18. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Chauffert B; Feuvret L; Bonnetain F; Taillandier L; Frappaz D; Taillia H; Schott R; Honnorat J; Fabbro M; Tennevet I; Ghiringhelli F; Guillamo JS; Durando X; Castera D; Frenay M; Campello C; Dalban C; Skrzypski J; Chinot O
Ann Oncol; 2014 Jul; 25(7):1442-1447. PubMed ID: 24723487
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
